However, the post-transplantation efficacy for SM with AML1::ETO + AML patients remains suboptimal, as relapses post-transplantation often result in treatment failure.The persistence of MCs in patients undergoing allo-HSCT represents an intriguing clinical observation (5). The gene discussed is RUNX1; the disease is acute myeloid leukemia.